Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma (Q33386405)

26 July 2017

Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma (English)

1 reference

multicenter clinical trial

26 July 2017

phase I clinical trial

0 references

0 references

1 reference

20

Kenneth C Anderson

1 reference

26 July 2017

1

Paul G Richardson

1 reference

26 July 2017

Robert Douglas Knight

18

object named as

Robert Knight

1 reference

26 July 2017

8

Nikhil C Munshi

1 reference

26 July 2017

9

Irene M Ghobrial

1 reference

26 July 2017

16

Teru Hideshima

1 reference

26 July 2017

7

Amitabha Mazumder

1 reference

26 July 2017

Constantine S Mitsiades

15

object named as

Constantine S Mitsiades

1 reference

26 July 2017

6

Robert L Schlossman

1 reference

26 July 2017

3

Sundar Jagannath

1 reference

26 July 2017

5

Melissa Alsina

1 reference

26 July 2017

19

Dixie-Lee Esseltine

1 reference

26 July 2017

4

David E Avigan

1 reference

26 July 2017

Edie Weller

2

1 reference

26 July 2017

Deborah Doss

10

1 reference

26 July 2017

Diane L Warren

11

1 reference

26 July 2017

Laura E Lunde

12

1 reference

26 July 2017

Mary McKenney

13

1 reference

26 July 2017

Carol Delaney

14

1 reference

26 July 2017

William Dalton

17

1 reference

26 July 2017

language of work or name

English

0 references

publication date

28 September 2009

1 reference

Journal of Clinical Oncology

26 July 2017

1 reference

26 July 2017

27

1 reference

26 July 2017

5713-5719

1 reference

26 July 2017

34

1 reference

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

26 July 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799050

Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799050

21 June 2018

Cancer statistics, 2008

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799050

Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799050

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799050

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799050

Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799050

21 June 2018

New drugs for myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799050

A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799050

A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799050

Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799050

Thromboembolism risk reduction in multiple myeloma patients treated with immunomodulatory drug combinations

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799050

Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799050

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799050

A phase 2 study of bortezomib in relapsed, refractory myeloma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799050

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799050

The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799050

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799050

The Functional Assessment of Cancer Therapy scale: development and validation of the general measure

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799050

Utility of bortezomib retreatment in relapsed or refractory multiple myeloma patients: a multicenter case series.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799050

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799050

The evolution of thalidomide and its IMiD derivatives as anticancer agents

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799050

The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799050

Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799050

Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799050

Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial

31 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19786667

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Clinically relevant end points and new drug approvals for myeloma

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19786667

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19786667

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1200/JCO.2009.22.2679

1 reference

26 July 2017

1 reference

26 July 2017

1 reference